Report cover image

Global Ophthalmic AAV Gene Therapy Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Jul 01, 2025
Length 194 Pages
SKU # APRC20117843

Description

Summary

According to APO Research, the global Ophthalmic AAV Gene Therapy market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Ophthalmic AAV Gene Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.

The Asia-Pacific market for Ophthalmic AAV Gene Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Ophthalmic AAV Gene Therapy market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.

The Europe market for Ophthalmic AAV Gene Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Ophthalmic AAV Gene Therapy market include GenSight Biologics (Pipeline) and Spark/Roche (Luxturna) etc. In 2024, the top three vendors accounted for approximately % of the market revenue.

This report presents an overview of global market for Ophthalmic AAV Gene Therapy, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Ophthalmic AAV Gene Therapy, also provides the value of main regions and countries. Of the upcoming market potential for Ophthalmic AAV Gene Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Ophthalmic AAV Gene Therapy revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Ophthalmic AAV Gene Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Ophthalmic AAV Gene Therapy company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.

Ophthalmic AAV Gene Therapy Segment by Company

GenSight Biologics (Pipeline)
Spark/Roche (Luxturna)

Ophthalmic AAV Gene Therapy Segment by Type

Subretinal Injection
Intravitreous Injection

Ophthalmic AAV Gene Therapy Segment by Application

Retinopathy
Optic Atrophy

Ophthalmic AAV Gene Therapy Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global Ophthalmic AAV Gene Therapy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Ophthalmic AAV Gene Therapy key companies, revenue, market share, and recent developments.
3. To split the Ophthalmic AAV Gene Therapy breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Ophthalmic AAV Gene Therapy market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Ophthalmic AAV Gene Therapy significant trends, drivers, influence factors in global and regions.
6. To analyze Ophthalmic AAV Gene Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ophthalmic AAV Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Ophthalmic AAV Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ophthalmic AAV Gene Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Ophthalmic AAV Gene Therapy industry.
Chapter 3: Detailed analysis of Ophthalmic AAV Gene Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Ophthalmic AAV Gene Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Ophthalmic AAV Gene Therapy in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

194 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Ophthalmic AAV Gene Therapy Market Size, 2020 VS 2024 VS 2031
1.3 Global Ophthalmic AAV Gene Therapy Market Size (2020-2031)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Ophthalmic AAV Gene Therapy Market Dynamics
2.1 Ophthalmic AAV Gene Therapy Industry Trends
2.2 Ophthalmic AAV Gene Therapy Industry Drivers
2.3 Ophthalmic AAV Gene Therapy Industry Opportunities and Challenges
2.4 Ophthalmic AAV Gene Therapy Industry Restraints
3 Ophthalmic AAV Gene Therapy Market by Company
3.1 Global Ophthalmic AAV Gene Therapy Company Revenue Ranking in 2024
3.2 Global Ophthalmic AAV Gene Therapy Revenue by Company (2020-2025)
3.3 Global Ophthalmic AAV Gene Therapy Company Ranking (2023-2025)
3.4 Global Ophthalmic AAV Gene Therapy Company Manufacturing Base and Headquarters
3.5 Global Ophthalmic AAV Gene Therapy Company Product Type and Application
3.6 Global Ophthalmic AAV Gene Therapy Company Establishment Date
3.7 Market Competitive Analysis
3.7.1 Global Ophthalmic AAV Gene Therapy Market Concentration Ratio (CR5 and HHI)
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.7.3 2024 Ophthalmic AAV Gene Therapy Tier 1, Tier 2, and Tier 3 Companies
3.8 Mergers and Acquisitions Expansion
4 Ophthalmic AAV Gene Therapy Market by Type
4.1 Ophthalmic AAV Gene Therapy Type Introduction
4.1.1 Subretinal Injection
4.1.2 Intravitreous Injection
4.2 Global Ophthalmic AAV Gene Therapy Sales Value by Type
4.2.1 Global Ophthalmic AAV Gene Therapy Sales Value by Type (2020 VS 2024 VS 2031)
4.2.2 Global Ophthalmic AAV Gene Therapy Sales Value by Type (2020-2031)
4.2.3 Global Ophthalmic AAV Gene Therapy Sales Value Share by Type (2020-2031)
5 Ophthalmic AAV Gene Therapy Market by Application
5.1 Ophthalmic AAV Gene Therapy Application Introduction
5.1.1 Retinopathy
5.1.2 Optic Atrophy
5.2 Global Ophthalmic AAV Gene Therapy Sales Value by Application
5.2.1 Global Ophthalmic AAV Gene Therapy Sales Value by Application (2020 VS 2024 VS 2031)
5.2.2 Global Ophthalmic AAV Gene Therapy Sales Value by Application (2020-2031)
5.2.3 Global Ophthalmic AAV Gene Therapy Sales Value Share by Application (2020-2031)
6 Ophthalmic AAV Gene Therapy Regional Value Analysis
6.1 Global Ophthalmic AAV Gene Therapy Sales Value by Region: 2020 VS 2024 VS 2031
6.2 Global Ophthalmic AAV Gene Therapy Sales Value by Region (2020-2031)
6.2.1 Global Ophthalmic AAV Gene Therapy Sales Value by Region: 2020-2025
6.2.2 Global Ophthalmic AAV Gene Therapy Sales Value by Region (2026-2031)
6.3 North America
6.3.1 North America Ophthalmic AAV Gene Therapy Sales Value (2020-2031)
6.3.2 North America Ophthalmic AAV Gene Therapy Sales Value Share by Country, 2024 VS 2031
6.4 Europe
6.4.1 Europe Ophthalmic AAV Gene Therapy Sales Value (2020-2031)
6.4.2 Europe Ophthalmic AAV Gene Therapy Sales Value Share by Country, 2024 VS 2031
6.5 Asia-Pacific
6.5.1 Asia-Pacific Ophthalmic AAV Gene Therapy Sales Value (2020-2031)
6.5.2 Asia-Pacific Ophthalmic AAV Gene Therapy Sales Value Share by Country, 2024 VS 2031
6.6 South America
6.6.1 South America Ophthalmic AAV Gene Therapy Sales Value (2020-2031)
6.6.2 South America Ophthalmic AAV Gene Therapy Sales Value Share by Country, 2024 VS 2031
6.7 Middle East & Africa
6.7.1 Middle East & Africa Ophthalmic AAV Gene Therapy Sales Value (2020-2031)
6.7.2 Middle East & Africa Ophthalmic AAV Gene Therapy Sales Value Share by Country, 2024 VS 2031
7 Ophthalmic AAV Gene Therapy Country-level Value Analysis
7.1 Global Ophthalmic AAV Gene Therapy Sales Value by Country: 2020 VS 2024 VS 2031
7.2 Global Ophthalmic AAV Gene Therapy Sales Value by Country (2020-2031)
7.2.1 Global Ophthalmic AAV Gene Therapy Sales Value by Country (2020-2025)
7.2.2 Global Ophthalmic AAV Gene Therapy Sales Value by Country (2026-2031)
7.3 USA
7.3.1 USA Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2020-2031)
7.3.2 USA Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.3.3 USA Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.4 Canada
7.4.1 Canada Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2020-2031)
7.4.2 Canada Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.4.3 Canada Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.5 Mexico
7.5.1 Mexico Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2020-2031)
7.5.2 Mexico Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.5.3 Mexico Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.6 Germany
7.6.1 Germany Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2020-2031)
7.6.2 Germany Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.6.3 Germany Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.7 France
7.7.1 France Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2020-2031)
7.7.2 France Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.7.3 France Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.8 U.K.
7.8.1 U.K. Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2020-2031)
7.8.2 U.K. Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.8.3 U.K. Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.9 Italy
7.9.1 Italy Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2020-2031)
7.9.2 Italy Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.9.3 Italy Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.10 Spain
7.10.1 Spain Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2020-2031)
7.10.2 Spain Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.10.3 Spain Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.11 Russia
7.11.1 Russia Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2020-2031)
7.11.2 Russia Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.11.3 Russia Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.12 Netherlands
7.12.1 Netherlands Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2020-2031)
7.12.2 Netherlands Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.12.3 Netherlands Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.13 Nordic Countries
7.13.1 Nordic Countries Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2020-2031)
7.13.2 Nordic Countries Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.13.3 Nordic Countries Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.14 China
7.14.1 China Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2020-2031)
7.14.2 China Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.14.3 China Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.15 Japan
7.15.1 Japan Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2020-2031)
7.15.2 Japan Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.15.3 Japan Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.16 South Korea
7.16.1 South Korea Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2020-2031)
7.16.2 South Korea Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.16.3 South Korea Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.17 India
7.17.1 India Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2020-2031)
7.17.2 India Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.17.3 India Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.18 Australia
7.18.1 Australia Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2020-2031)
7.18.2 Australia Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.18.3 Australia Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.19 Southeast Asia
7.19.1 Southeast Asia Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2020-2031)
7.19.2 Southeast Asia Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.19.3 Southeast Asia Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.20 Brazil
7.20.1 Brazil Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2020-2031)
7.20.2 Brazil Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.20.3 Brazil Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.21 Argentina
7.21.1 Argentina Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2020-2031)
7.21.2 Argentina Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.21.3 Argentina Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.22 Chile
7.22.1 Chile Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2020-2031)
7.22.2 Chile Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.22.3 Chile Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.23 Colombia
7.23.1 Colombia Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2020-2031)
7.23.2 Colombia Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.23.3 Colombia Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.24 Peru
7.24.1 Peru Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2020-2031)
7.24.2 Peru Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.24.3 Peru Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.25 Saudi Arabia
7.25.1 Saudi Arabia Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2020-2031)
7.25.2 Saudi Arabia Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.25.3 Saudi Arabia Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.26 Israel
7.26.1 Israel Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2020-2031)
7.26.2 Israel Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.26.3 Israel Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.27 UAE
7.27.1 UAE Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2020-2031)
7.27.2 UAE Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.27.3 UAE Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.28 Turkey
7.28.1 Turkey Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2020-2031)
7.28.2 Turkey Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.28.3 Turkey Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.29 Iran
7.29.1 Iran Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2020-2031)
7.29.2 Iran Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.29.3 Iran Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.30 Egypt
7.30.1 Egypt Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2020-2031)
7.30.2 Egypt Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.30.3 Egypt Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 GenSight Biologics (Pipeline)
8.1.1 GenSight Biologics (Pipeline) Comapny Information
8.1.2 GenSight Biologics (Pipeline) Business Overview
8.1.3 GenSight Biologics (Pipeline) Ophthalmic AAV Gene Therapy Revenue and Gross Margin (2020-2025)
8.1.4 GenSight Biologics (Pipeline) Ophthalmic AAV Gene Therapy Product Portfolio
8.1.5 GenSight Biologics (Pipeline) Recent Developments
8.2 Spark/Roche (Luxturna)
8.2.1 Spark/Roche (Luxturna) Comapny Information
8.2.2 Spark/Roche (Luxturna) Business Overview
8.2.3 Spark/Roche (Luxturna) Ophthalmic AAV Gene Therapy Revenue and Gross Margin (2020-2025)
8.2.4 Spark/Roche (Luxturna) Ophthalmic AAV Gene Therapy Product Portfolio
8.2.5 Spark/Roche (Luxturna) Recent Developments
9 Concluding Insights
10 Appendix
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.